These problems are mild and get better over time
For muscle-building, the peptides ipamorelin and CJC-1295 are advertised as stimulating growth hormone release
Proposed mechanisms include enhanced insulinotropic activity, improved adipose tissue handling of nutrients, central effects on appetite and reward pathways, and improved tolerability or pharmacodynamic balance when combined with GLP-1 receptor agonism
*Note: Dosing may be doubled in serious conditions
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Every year, innovators rush into GLP studies before they're truly ready
[DOI] [PubMed] [Google Scholar] 94.Pollak NM, Jaeger D, Kolleritsch S, Zimmermann R, Zechner R, Lass A, et al
